ZyVersa Therapeutics, Inc. ZVSA
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -99.25%
- 1 year
- -99.26%
- Open
- 0.0455
- Prev close
- 0.001
- Mkt cap
- 8.10K
- Vol
- 77.96K
- Avg vol
- 8.93K
- EPS
- -2.79
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.0415
- High
- 0.05
- Forward P/E
- -0.24
- Beta
- 0.64
- Short ratio
- 0.19
- Inst. own
- 4.47%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 9, 2024
- 50-d avg
- 1.52
- 200-d avg
- 3.80
- 1y target
- 20.00
6M chart
Signals (22)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 13, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 1, 2026 | 1 month ago |
| SMA: Bearish | Sep 30, 2026 | 1 month ago |
| SMA: Bullish | Sep 29, 2026 | 1 month ago |
| SMA: Bearish | Sep 21, 2026 | 1 month ago |
| SMA: Bullish | Sep 18, 2026 | 1 month ago |
| MACD: Buy Signal | Jul 24, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 2, 2026 | 4 months ago |
| MACD: Buy Signal | Jul 1, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 29, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 26, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 22, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 12, 2026 | 4 months ago |
| SMA: Bearish | Jun 8, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 8, 2026 | 4 months ago |
| SMA: Bullish | Jun 5, 2026 | 5 months ago |
| MACD: Buy Signal | Jun 5, 2026 | 5 months ago |
| MACD: Sell Signal | Jun 2, 2026 | 5 months ago |
| SMA: Bearish | Jun 1, 2026 | 5 months ago |
| SMA: Bullish | May 28, 2026 | 5 months ago |
Newest 20 of 22.
Key statistics
- Market cap
- 2.74M
- Enterprise value
- 1.04M
- Trailing P/E
- 0.00
- Forward P/E
- -0.24
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.04
- EPS (TTM)
- 491.97
- Beta
- 0.64
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -5.54M
- Total cash
- 119.49K
- Total debt
- 0
- Return on equity
- -152.23%
- Shares outstanding
- 2.34M
- Short % of float
- 4.24%
- 50-day average
- 1.52
- 200-day average
- 3.80
Analyst view
Consensus: none
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 9, 2024
Expected Aug 9, 2024. Consensus EPS estimate -2.73.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -5.80 | -2.43 | +3.37 | +58.10% |
| Aug 9, 2024 | Jun 1, 2024 | -5.20 | -3.31 | +1.89 | +36.35% |
| Aug 9, 2024 | Jun 1, 2024 | -5.20 | — | — | — |
| May 15, 2024 | Mar 1, 2024 | -3.70 | — | — | — |
| May 15, 2024 | Mar 1, 2024 | -3.70 | -4.53 | -0.83 | -22.43% |
| Mar 26, 2024 | Dec 1, 2023 | -2.14 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 26, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Mar 12, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Feb 29, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About ZyVersa Therapeutics, Inc.
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- zyversa.com
News
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- 12 Health Care Stocks Moving In Tuesday's Intraday Session
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- Why Worthington Steel Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket
- 12 Health Care Stocks Moving In Wednesday's After-Market Session
- 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- 12 Health Care Stocks Moving In Monday's After-Market Session
Your note
Sign in to keep a note on ZVSA — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Tower Research Capital LLC (TRC) | 0.11% | 2,566 | 3.00K | Sep 29, 2024 |
| UBS Group AG | 0.02% | 433 | 506 | Sep 29, 2024 |
| JP Morgan Chase & Company | 0.00% | 1 | 1 | Sep 29, 2024 |
| Royal Bank of Canada | 0.00% | 52 | 60 | Sep 29, 2024 |
| Bank of America Corporation | 0.00% | 8 | 9 | Sep 29, 2024 |
| Morgan Stanley | 0.00% | 1 | 1 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.21% | 4,950 | 5.79K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.07% | 1,614 | 1.89K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.00% | 50 | 58 | Sep 29, 2024 |